Hepatitis B Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Hepatitis B tests Market Report Overview

The hepatitis B tests market size was valued at $1.75 billion in 2023. The hepatitis B tests market will grow at a CAGR of more than 2% from 2023 to 2033. Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV). The virus attacks the liver and can cause acute and chronic disease, which might lead to liver failure, liver cancer or liver cirrhosis, kidney disease, and/or inflammation of blood vessels. The virus can be transmitted through blood or other bodily fluids by transfusion, sexual contact, sharing of needles, accidental needle sticks, and mother-to-child transmission.

Hepatitis B Tests Market Outlook 2023-2033 ($ Billion)

Buy the Full Report for More Insights on the Hepatitis B Tests Market Forecast, Download a Free Sample Report

The hepatitis B tests market research report explains the market behavior, which will help identify quantitative market trends within in vitro diagnostics therapeutic areas. The report has extensively covered regional-wise quantitative data, highlighting the number of hepatitis B tests across labs, which will help in identifying untapped market opportunities. The hepatitis B tests market model also discusses the detailed impact of COVID-19 on the hepatitis B tests market for 2020 and beyond.

Hepatitis B Tests Market Dynamics

Hepatitis B is a common cause of liver disease across the globe and remains a major issue for most governments even though an effective vaccine has been available since 1982. HBV tests are performed for several purposes, including screening of suspected infection patients and diagnosis; monitoring of HBV-positive patients; screening of pregnant women, and screening of donors of human cells, tissues, and cellular & tissue-based products (HCT/P).

The incidence of HBV is expected to increase in many countries during the forecast period, across all geographical regions. The countries expected to be impacted by the condition are the US, France, Germany, Spain, Austria, Belgium, the Czech Republic, Denmark, Finland, Ireland, the Netherlands, Norway, New Zealand, Brazil, and Chile. The rise in HBV diagnosis incidence will increase the number of tests performed as well as improve disease awareness and continuation of strong screening initiatives.

Buy the Full Report for Additional Hepatitis B Tests Market Dynamics, Download a Free Sample Report

Hepatitis B tests Market Segments

The key segments in the hepatitis B tests market are Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs), and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs. In 2023, the Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests segment dominated the market share. The segment is likely to dominate the market during the forecast period.

Hepatitis B Tests Market Analysis by Segments, 2023 (%)

Buy the Full Report for More Segment-Wise Insights about the Hepatitis B Tests Market Segments, Download a Free Sample Report

Hepatitis B Tests Market Segmentation by Regions

The key regions in the hepatitis B tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, North America was the leading regional segment in the hepatitis B tests market.

The US and Canadian markets are both expected to increase, while a slight decline is forecast in the Mexican market. The number of hepatitis B tests performed for prevalent cases is expected to increase in all three North American countries, with the number of suspected infection cases also expected to increase in the US and Mexico. However, these are not the only drivers of market growth; a large proportion of tests are performed on pregnant women and donors of human cells, tissues, and cellular and tissue-based products will also drive the market’s growth.

Hepatitis B tests Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Regional Insights in the Hepatitis B tests Market, Download A Free Sample Report

Hepatitis B tests Market – Competitive Landscape

The key companies in the hepatitis B tests market are Siemens Healthineers AG, Roche Diagnostics International Ltd, Abbott Laboratories, Quidel Corp, and Bio-Rad Laboratories Inc among others. In 2023, Siemens Healthineers AG accounted for the highest hepatitis B tests market share and value.

Hepatitis B Tests Market Analysis by Companies, 2023 (%)

Buy the Full Report for More Company-Wise Insights into the Hepatitis B Tests Market, Download a Free Sample Report

Segments Covered in this Report.

Hepatitis B tests Segment Outlook ($ Million, 2015-2033)

• Hepatitis B Tests
  • Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests
  • Hepatitis B Nucleic Acid Amplification Tests (NAATs)
• Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs

Hepatitis B tests Regional Outlook ($ Million, 2015-2033)

• Asia-Pacific
• Europe
• Middle East and Africa
• North America
• South and Central America

Key Inclusions of the market model are:

Currently marketed hepatitis B tests market and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total hepatitis B tests market revenue by segment and market outlooks from 2015-2033.
• Market-level data on units, average selling prices, and market values.

Global, Regional and Country level market specific insights:

• Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the Hepatitis B tests market.
• Competitive dynamics insights and trends provided for the hepatitis B tests market.

Get an in-depth understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Quidelortho Corp, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, DiaSorin SpA, and others.

Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is crucial for the following stakeholders to help in achieving strategic business goals:

• CMO executives who must have a deep understanding of the hepatitis B tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives must understand crucial components of the supply base to make decisions about supplier selection and management.
• Private equity investors who need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

• Understand the impact of COVID-19 on hepatitis B tests.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving hepatitis B tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis B tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific hepatitis B tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.